Stock listing

Alphamab Oncology

Selected listing: 9966 · HKEX · HKD · HK

Alphamab Oncology (HKEX:9966), Health Technology. Latest release Sep 28, 2026: Next Day Disclosure Return.

9966:HKEXHKDHKUpdated October 2, 2026

Ticker: HKEX:9966
Asset type: Stock
Sector: Health Technology
Industry: Biotechnology
Exchange: HKEX
Currency: HKD

About Alphamab Oncology

Alphamab Oncology is a public company listed on the Hong Kong Stock Exchange under the ticker 9966. The company focuses on developing innovative therapies for cancer treatment.

Latest news from Alphamab Oncology

Next Day Disclosure Return

September 28, 2026

2026 ASCO Preview | Alphamab Oncology to Present Clinical Data of TROP2/HER3 Bispecific ADC JSKN016 for HER2-Negative Breast Cancer

April 22, 2026

2026 ASCO Preview | Results from Phase III Study of Anbenitamab (KN026) Combined with HB1801 in Neoadjuvant Treatment for Breast Cancer Selected for LBA Oral Presentation

April 22, 2026

Alphamab Oncology Announces the Phase III Clinical Study of Anbenitamab (KN026) Combined with HB1801 as Neoadjuvant Treatment for Breast Cancer Has Met the Primary Endpoint

April 1, 2026

Alphamab Oncology Reports Full Year 2025 Financial Results and Business Highlights

March 26, 2026

All Alphamab Oncology news →

Research Alphamab Oncology

Alphamab Oncology company profile

View the public company page for Alphamab Oncology on 6ix.

Alphamab Oncology news

Read company news and market updates connected to Alphamab Oncology.

Alphamab Oncology investor events

Find investor webinars, events, and replay context for Alphamab Oncology.